SANTA FE, N.M., April 20 /PRNewswire/ -- Bioreason, Inc. announced today that Dr. Andrew DePristo has joined the Company as President & CEO.
Dr. DePristo has been involved in the life and chemical science industry and research for several decades. He was most recently the Sr. Director of Research and Preclinical Development Information Systems at Amgen, the world's largest biotechnology company.
I am delighted to join and lead the world-class cheminformatics team at Bioreason which has developed the terrific product, Classpharmer(TM) Suite, and licensed it to over 25 top pharmaceutical and biotechnology companies," said Dr. DePristo. "The challenges ahead are significant but the opportunities are even greater -- to develop sophisticated knowledge-based software that helps accelerate the discovery of much needed new medicines."
Prior to Amgen, Dr. DePristo served as founding President of GeneData AG's U.S. subsidiary, Waltham, MA, and South San Francisco, CA, which provided bioinformatics software for target discovery and analysis. He was the Vice-President of Bioinformatics, Information Technology and Emerging Technology at Genome Therapeutics Corp, a biotech company focused on the development of antimicrobials. He serves on the Advisory Boards for Rockwater Capital Partners, LLC, Portland, ME, which is a royalty-based investment company, and the College of Life Sciences, U of Maryland, College Park, MD. Dr. DePristo earned a Ph.D. in Theoretical Chemistry from that institution and went on to author over 100 refereed articles in theoretical chemistry, and to present over 100 invited talks at institutions, national and international scientific meetings
"The company feels fortunate to have found Andrew DePristo. We believe his science background, his demonstrated leadership abilities, and his management skills in growing companies will help Bioreason achieve its goals of expansion and rapid growth," said Michael Grantham, Chairman of the Bioreason Board of Directors.
Bioreason, Inc., is headquartered in Santa Fe, New Mexico, with sales and support offices in Strasbourg (France) and Tokyo. Bioreason provides knowledge-based software, services, and collaborations that automate and optimize the drug discovery process including validation of hits and optimization of leads. The Classpharmer(TM) Suite enables generation of targeted compound screening lists and the automated extraction of structure-activity relationships to predict both potency and toxicological properties of lead compounds. For information on the company, see http://www.bioreason.com/.
For additional information, please contact Debra R. Guerin, Managing Director, International Venture Fund, +1-650-330-1210, firstname.lastname@example.org.